ASCO 2021丨一文速览血液肿瘤口头报告

标题：OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)

标题：Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study

标题：Phase 2 results of the ZUMA-3 study evaluating KTE-X19， an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy， in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

标题：The results of multicenter phase II， double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302)

标题：Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease

标题：Prospective longitudinal evaluation of microbiome diversity in patients with hematological malignancy undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

标题：Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial

标题：Efficacy and safety of aspacytarabine (BST-236) as a single-agent， first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy

标题：Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia

标题：First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia

标题：Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study

标题：First-in-human study of lisaftoclax (APG-2575)， a novel BCL-2 inhibitor (BCL-2i)， in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs)

标题：ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS

标题：Real-world (RW) treatment (tx) patterns and outcomes of 3，455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice

标题：The combination of venetoclax， lenalidomide， and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability

标题：Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance)

标题：CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL)

标题：Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial

标题：Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible， newly diagnosed (NDTE) multiple myeloma (MM)

标题：Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab， bortezomib， lenalidomide， cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial

标题：Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients

标题：Subcutaneous daratumumab + bortezomib， cyclophosphamide， and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study

标题：Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib， thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2

标题：Ciltacabtagene autoleucel， a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy， in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1

标题：Efficacy and safety of elranatamab (PF-06863135)， a B-cell maturation antigen (BCMA)-CD3 bispecific antibody， in patients with relapsed or refractory multiple myeloma (MM)

标题：Updated phase 1 results of teclistamab， a B-cell maturation antigen (BCMA) × CD3 bispecific antibody， in relapsed/refractory multiple myeloma (MM)

标题：Updated results of a phase 1， first-in-human study of talquetamab， a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody， in relapsed/refractory multiple myeloma (MM)